Which Is Better for Weight Loss: Wegovy or Zepbound?

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved medications for chronic weight management, but they work through different mechanisms and produce different weight-loss timelines. PlexusDx offers compounded versions of both medications at transparent, dose-independent pricing, allowing patients to choose the option best suited to their body and goals.

How Wegovy and Zepbound Work Differently in Your Body

Wegovy activates one receptor in the brain and gut called the GLP-1 receptor, which signals fullness and reduces appetite. This single-pathway approach has been studied for over a decade and produces reliable, sustained weight loss in most patients. The medication slows stomach emptying, which keeps you feeling satisfied longer after meals.

Zepbound targets two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-receptor activation creates a more aggressive satiety signal and also improves how your body regulates blood sugar. Early clinical trials suggest this two-pathway approach may produce faster initial weight loss, particularly in the first 12 weeks of treatment.

Weight Loss Results: Speed and Sustained Outcomes

In the STEP trials, semaglutide users achieved an average weight loss of 10–15% of body weight over 68 weeks. Results were dose-dependent and consistent across age groups and BMI ranges. Most patients experienced noticeable appetite suppression within the first 2–3 weeks, with steady monthly weight loss of 1–2 pounds on average after dose stabilization.

Tirzepatide trials (SURMOUNT-1 and SURMOUNT-4) demonstrated average weight loss of 20–22% of body weight over 72 weeks at the highest maintenance doses. Notably, 35% of tirzepatide users achieved at least 25% weight loss compared to 16% with semaglutide. The faster initial phase (weeks 4–12) often shows more dramatic results, making tirzepatide appealing for patients seeking quicker metabolic shifts.

Side Effects, Tolerability, and Dose Escalation

Both medications can cause nausea, vomiting, and gastrointestinal upset, particularly during the dose-escalation phase. Semaglutide's single-pathway mechanism generally produces milder side effects, making it a suitable entry point for patients new to GLP-1 therapy. Most side effects resolve within 1–2 weeks as the body adapts, and patients on a stable maintenance dose report minimal ongoing symptoms.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cost, Access, and Personalized Dosing With PlexusDx

PlexusDx offers compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan and compounded tirzepatide at $289/mo month-to-month, or from $249/mo on the 6-month plan from licensed 503A pharmacies. Both medications are available nationwide without insurance or membership fees, and both are HSA/FSA eligible. PlexusDx's transparent pricing model means your dose may increase as your body adapts, but your monthly cost remains flat—no surprise charges tied to dose level.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which medication causes less nausea: Wegovy or Zepbound?

Semaglutide (Wegovy) typically produces milder nausea because it activates only one receptor pathway. Tirzepatide's dual-pathway mechanism can cause stronger initial GI effects, though most patients adapt within 1–2 weeks. PlexusDx patients can discuss side-effect profiles with their care team to choose the best starting medication for their tolerance level.

Will I lose weight faster on Zepbound than Wegovy?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I switch between semaglutide and tirzepatide if one isn't working?

Yes, switching is medically safe and common practice. Many patients start with semaglutide for its gentler tolerability, then transition to tirzepatide after stabilizing if they want stronger results. PlexusDx supports medication transitions and can compound either medication at your preferred dosing schedule.

Why is PlexusDx tirzepatide more affordable than brand-name Zepbound?

PlexusDx tirzepatide is compounded by licensed 503A pharmacies from the same active pharmaceutical ingredient as brand Zepbound, but without brand marketing costs or distributor markups. PlexusDx passes those savings directly to patients: tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) regardless of dose level.

What does the Precision Peptide Genetic Test tell me about Wegovy vs. Zepbound?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy Vs Zepbound Weight Loss
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Zepbound For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.